Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting-Reference-Cited by-同舟云学术

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

Published:2013-08 Issue:8 Volume:3 Page:e129-e129
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Feller N,van der Velden V H J,Brooimans R A,Boeckx N,Preijers F,Kelder A,de Greef I,Westra G,te Marvelde J G,Aerts P,Wind H,Leenders M,Gratama J W,Schuurhuis G J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201327.pdf

Reference19 articles.

1. Béné MC, Kaeda JS . How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica 2009; 94: 1135–1150.

2. San Miguel JF, Vidriales MB, Lopez-Berges C, az-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746–1751.

3. San Miguel JF, Martínez A, Macedo A, Vidriales MB, López-Berges C, González M et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465–2470.

4. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948–3952.

5. Feller N, van der Pol MA, van Stijn A, Weijers GW, Westra AH, Evertse BW et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004; 18: 1380–1390.

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pretransplantation risk factors for MRD after allogeneic stem cell transplantation in AML patients: A prospective study;2024-06-07

2. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia;Advances in Oncology;2024-05

3. Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia;Leukemia;2024-01-25

4. A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia;Cytometry Part A;2023-12-08

5. Minimal residual disease in acute leukemia based on the insight of molecular genetics monitoring;International Journal of ADVANCED AND APPLIED SCIENCES;2023-05